Target Price | GBP137.60 |
Price | GBP113.66 |
Potential | 21.06% |
Number of Estimates | 26 |
26 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP137.60. This is 21.06% higher than the current stock price. The highest price target is GBP189.67 66.88% , the lowest is GBP105.46 7.22% . | |
A rating was issued by 33 analysts: 28 Analysts recommend AstraZeneca to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 21.06% . Most analysts recommend the AstraZeneca stock at Purchase. |
24 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP44.4b . This is 5.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP46.2b 9.14% , the lowest is GBP41.4b 2.06% .
This results in the following potential growth metrics:
2024 | GBP42.3b | 14.82% |
---|---|---|
2025 | GBP44.4b | 5.01% |
2026 | GBP47.4b | 6.64% |
2027 | GBP50.3b | 6.14% |
2028 | GBP53.2b | 5.79% |
2029 | GBP55.9b | 5.07% |
18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.3b . This is 11.14% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP18.3b 33.17% , the lowest is GBP12.8b 7.02% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP14.0b | 21.08% |
---|---|---|
2025 | GBP15.3b | 9.50% |
2026 | GBP17.1b | 11.74% |
2027 | GBP19.0b | 10.96% |
2028 | GBP20.1b | 6.03% |
2029 | GBP24.1b | 19.76% |
2024 | 33.02% | 5.44% |
---|---|---|
2025 | 34.43% | 4.28% |
2026 | 36.08% | 4.79% |
2027 | 37.72% | 4.55% |
2028 | 37.80% | 0.21% |
2029 | 43.09% | 13.99% |
16 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP7.5b . This is 36.14% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP8.5b 53.41% , the lowest is GBP4.9b 10.82% .
This results in the following potential growth metrics and future Net Margins:
2024 | GBP5.5b | 14.89% |
---|---|---|
2025 | GBP7.5b | 36.52% |
2026 | GBP9.1b | 21.24% |
2027 | GBP10.3b | 13.21% |
2028 | GBP11.6b | 12.02% |
2029 | GBP14.3b | 23.47% |
2024 | 13.01% | 0.05% |
---|---|---|
2025 | 16.91% | 30.00% |
2026 | 19.23% | 13.72% |
2027 | 20.51% | 6.66% |
2028 | 21.72% | 5.90% |
2029 | 25.52% | 17.50% |
16 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP4.85 . This is 36.24% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP5.46 53.37% , the lowest is GBP3.17 10.96% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.55 | 14.89% |
---|---|---|
2025 | GBP4.85 | 36.62% |
2026 | GBP5.88 | 21.24% |
2027 | GBP6.65 | 13.10% |
2028 | GBP7.45 | 12.03% |
2029 | GBP9.20 | 23.49% |
Current | 31.94 | 7.42% |
---|---|---|
2025 | 23.45 | 26.58% |
2026 | 19.34 | 17.53% |
2027 | 17.09 | 11.63% |
2028 | 15.25 | 10.77% |
2029 | 12.35 | 19.02% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.41 and an P/S ratio of 3.97 .
This results in the following potential growth metrics and future valuations:
Current | 4.63 | 7.03% |
---|---|---|
2025 | 4.41 | 4.74% |
2026 | 4.14 | 6.22% |
2027 | 3.90 | 5.79% |
2028 | 3.68 | 5.47% |
2029 | 3.51 | 4.83% |
Current | 4.17 | 7.27% |
---|---|---|
2025 | 3.97 | 4.79% |
2026 | 3.72 | 6.22% |
2027 | 3.50 | 5.79% |
2028 | 3.31 | 5.47% |
2029 | 3.15 | 4.83% |
Analyst | Rating | Action | Date |
---|---|---|---|
Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Mar 07 2025 |
JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Feb 19 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 27 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 06 2025 |
JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Nov 22 2024 |
JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Nov 07 2024 |
Analyst Rating | Date |
---|---|
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Mar 07 2025 |
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Feb 19 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 27 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 06 2025 |
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Nov 22 2024 |
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Nov 07 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.